drugset
Drugs / ET-01
last change Mar 2025 re-read 3 minutes ago

ET-01

Cell therapy targets BCL11A

Developed for
beta thalassemia
Investigated by
EdiGene (GuangZhou) Inc. · EdiGene Inc. · Institute of Hematology & Blood Diseases Hospital, China · The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army · The Affiliated Hospital Of Guizhou Medical University · Zunyi Medical College

Trials 3

today NCT05752123 · not/applicable NCT04390971 · not/applicable NCT04925206 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT04925206 Aug 2021 → Jan 2024 beta thalassemia EdiGene (GuangZhou) Inc. Terminated No outcome recorded
Phase not applicable2 trials
— NCT05752123 Feb 2023 → Jan 2024 beta thalassemia EdiGene (GuangZhou) Inc. Terminated No outcome recorded
— NCT04390971 Feb → Mar 2023 beta thalassemia Institute of Hematology & Blood Diseases Hospital, China Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as ET-01 ClinicalTrials.gov intervention name — accepted as the source's own label NCT04925206 ↗
2

NCT05752123 ↗

NCT04390971 ↗
Modality Cell therapy “BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.” NCT04390971 ↗
Route Intravenous “ET-01 IV infusion” NCT04390971 ↗
Target BCL11A “BCL11A Enhancer modified Autologous Hematopoietic Stem Cells.” NCT04390971 ↗